Evidence map›Paper›PMID 40040701›Full record

ArticleFrontiers in immunology2025

Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients.

Vincenzo Raimondi, Paola Storti, Rosanna Vescovini, Valentina Franceschi, Denise Toscani, Laura Notarfranchi, Anna Benedetta Dalla Palma, Nicolas Thomas Iannozzi, Sergio Minesso, Matteo Scita and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Vincenzo Raimondi *Department of Medicine and Surgery, University of Parma, Parma, Italy.
Paola Storti *Department of Medicine and Surgery, University of Parma, Parma, Italy.
Rosanna VescoviniDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Valentina FranceschiDepartment of Medical-Veterinary Science, University of Parma, Parma, Italy.
Denise ToscaniDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Laura NotarfranchiHematology, "Azienda Ospedaliero-Universitaria di Parma", Parma, Italy.
Anna Benedetta Dalla PalmaHematology, "Azienda Ospedaliero-Universitaria di Parma", Parma, Italy.
Nicolas Thomas IannozziDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Sergio MinessoDepartment of Medical-Veterinary Science, University of Parma, Parma, Italy.
Matteo ScitaHematology, "Azienda Ospedaliero-Universitaria di Parma", Parma, Italy.
Oxana LunguDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Mattia DessenaDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Gaetano DonofrioDepartment of Medical-Veterinary Science, University of Parma, Parma, Italy.
Nicola GiulianiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The stability of immune responses to SARS-CoV-2 vaccines, especially concerning the cross-reactive recognition of the Omicron variant, remains incompletely characterized in multiple myeloma (MM) patients. This study evaluated humoral responses in 29 MM patients and cellular responses in a subset of 19 MM patients, specific to Wuhan and Omicron spike proteins, between 16 and 26 weeks following the third vaccine dose. After 26 weeks, we highlighted a significant reduction in the neutralizing antibodies to both spikes and the percentages of IFN-γ

Indexed as

COVID-19COVID-19 VaccinesImmunity, CellularImmunity, HumoralMultiple MyelomaSARS-CoV-2AdultAgedAntibodies, NeutralizingAntibodies, ViralCD8-Positive T-LymphocytesFemaleFollow-Up StudiesHumansMaleMiddle AgedAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2breakthrough infectionhumoral immunitymultiple myelomaOmicron variantSARS-CoV-2 vaccinationT cell response

Identifiers

PMID40040701
PMCPMC11876378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.